Skip to Content
Authors Djamali A, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M
Author Profile(s)
Journal Am. J. Transplant. Volume: 14 Issue: 2 Pages: 255-71
Publish Date 2014 Feb
PubMed ID 24401076
PMC ID 4285166

Advances in multimodal immunotherapy have significantly reduced acute rejection rates and substantially improved 1-year graft survival following renal transplantation. However, long-term (10-year) survival rates have stagnated over the past decade. Recent studies indicate that antibody-mediated rejection (ABMR) is among the most important barriers to improving long-term outcomes. Improved understanding of the roles of acute and chronic ABMR has evolved in recent years following major progress in the technical ability to detect and quantify recipient anti-HLA antibody production. Additionally, new knowledge of the immunobiology of B cells and plasma cells that pertains to allograft rejection and tolerance has emerged. Still, questions regarding the classification of ABMR, the precision of diagnostic approaches, and the efficacy of various strategies for managing affected patients abound. This review article provides an overview of current thinking and research surrounding the pathophysiology and diagnosis of ABMR, ABMR-related outcomes, ABMR prevention and treatment, as well as possible future directions in treatment.

Full Text Full text available on PubMed Central Copyright © 2017 The Board of Regents of the University of Wisconsin System